Xiuhtlaulli López Suástegui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiuhtlaulli López Suástegui has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Rivera Mora1 shared publication
- Erik Rafflenbeul
Department of Cardiology, Schön Klinik Hamburg Eilbek , Hamburg
1 shared publication - Han Naung Tun
Geisel School of Medicine, Dartmouth College , Hanover, NH, USA
1 shared publication May Thu Kyaw
Heart and Vascular Centre, Victoria Hospital, Yangon, Myanmar
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by IntechOpen
Trauma-Induced Coagulopathy: Mechanisms, Monitoring and Clinical Pearls in Critical Care
Trauma-induced coagulopathy (TIC) is an early and clinically relevant disturbance of hemostasis that develops after severe injury and is closely associated with major hemorrhage, transfusion requirements, organ failure, and death. In this chapter, we review TIC from a practical critical care perspective, linking underlying mechanisms with bedside monitoring and treatment. We discuss conventional coagulation tests, viscoelastic assays, damage control resuscitation, balanced transfusion, fibrinogen and calcium replacement, tranexamic acid, and individualized hemostatic support, while highlighting clinical pearls, common pitfalls, and future directions relevant to everyday practice.
- 21 August 2026
- Published by IntechOpen
Open AccessTrauma-Induced Coagulopathy: Mechanisms, Monitoring and Clinical Pearls in Critical Care
Trauma-induced coagulopathy (TIC) is an early and clinically relevant disturbance of hemostasis that develops after severe injury and is closely associated with major hemorrhage, transfusion requirements, organ failure, and death. In this chapter, we review TIC from a practical critical care perspective, linking underlying mechanisms with bedside monitoring and treatment. We discuss conventional coagulation tests, viscoelastic assays, damage control resuscitation, balanced transfusion, fibrinogen and calcium replacement, tranexamic acid, and individualized hemostatic support, while highlighting clinical pearls, common pitfalls, and future directions relevant to everyday practice.
- Open Access
- 13 May 2022
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 17, e11
Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.
- 13 May 2022
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 17, e11
Open AccessRole of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.